 The study aimed to develop and validate serologic assays for the detection of severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, antibodies in patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections. The study demonstrated that most PCR-confirmed SARS-CoV-2 infected person seroconverted by two weeks after disease onset and found that commercial S1 IgG or IgA ELISA's were of lower specificity, with the IgA ELISA showing higher sensitivity. The validated assays described can be instrumental for detection of SARS-CoV-2, specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies. This article was authored by Nisreen Maakba, Marcel A. Muller, Wentauli, and others.